Clera - Your AI talent agent
Back to Companies
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc.

Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist...

51-200 employees

Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com.

Frequently Asked Questions

How many employees does Kailera Therapeutics, Inc. have?

Kailera Therapeutics, Inc. has around 126 employees. As a Biotechnology Research company, they are actively growing their team with 0 open positions.

Why should I join Kailera Therapeutics, Inc.?

Kailera Therapeutics, Inc. is a leading Biotechnology Research company offering exciting career opportunities. With 0 open positions, now is a great time to join their growing team.

What does Kailera Therapeutics, Inc. do?

Kailera Therapeutics, Inc. is a Biotechnology Research company. Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced progr...